GlassScriptPhysician profile
Vatsala Katragadda
NPI 1841270634
$6,988.26
in general payments reported to CMS, 2019-2025
51 companies · $22.02 in 2025
The $22.02 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $911 · 2023: $3,169 · 2024: $2,886 · 2025: $22.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,015 · Long Term Medical Supply Or Device Loan: $881 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,014.91 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,162.69 | 2022-2024 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $534.50 | 2022-2024 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $473.64 | 2023-2024 | Opdivo, Krazati |
| Pfizer INC. | $418.52 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $414.76 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $284.80 | 2022-2024 | Trodelvy |
| Daiichi Sankyo INC. | $259.78 | 2022-2024 | Enhertu, Injectafer, Vanflyta |
| Astellas Pharma US INC | $246.29 | 2022-2024 | Padcev, Xtandi |
| Eisai INC. | $200.18 | 2022-2024 | |
| Incyte Corporation | $189.32 | 2023 | Jakafi |
| Amgen INC. | $168.76 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $153.46 | 2022-2024 | Alunbrig, Ninlaro, Fruzaqla |
| Janssen Biotech, INC. | $148.16 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Rigel Pharmaceuticals, INC. | $136.27 | 2022-2024 | Rezlidhia, Tavalisse |
| Genzyme Corporation | $133.95 | 2022-2024 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $132.71 | 2022-2024 | Lunsumio, Polivy, Columvi |
| Exelixis INC. | $130.89 | 2022-2024 | Cabometyx |
| Mirati Therapeutics, INC. | $127.26 | 2023-2024 | Krazati |
| Celgene Corporation | $113.76 | 2022-2023 | Reblozyl, Pomalyst, Opdualag |
| Ipsen Biopharmaceuticals, INC | $106.79 | 2022-2024 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $103.83 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $98.98 | 2023-2025 | Jemperli, Zejula |
| Kite Pharma, INC. | $93.56 | 2023 | |
| Seagen INC. | $92.94 | 2022-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $84.40 | 2022-2024 | |
| Tersera Therapeutics LLC | $80.72 | 2023 | Quzyttir, Zoladex |
| Sanofi-Aventis U.S. LLC | $77.99 | 2022 | |
| Abbvie INC. | $66.30 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $57.59 | 2023-2024 | Zepzelca |
| Deciphera Pharmaceuticals INC. | $51.28 | 2023-2024 | Qinlock |
| Karyopharm Therapeutics INC. | $50.78 | 2022-2023 | Xpovio |
| Adaptive Biotechnologies Corporation | $48.27 | 2024 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $47.41 | 2023-2024 | Monoferric |
| Morphosys, US INC. | $46.46 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $45.72 | 2022-2023 | Beleodaq |
| Beigene USA, INC. | $39.37 | 2023 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $39.21 | 2023-2024 | Ultomiris |
| Puma Biotechnology, INC. | $39.14 | 2024 | |
| Springworks Therapeutics, INC. | $31.91 | 2024 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $27.02 | 2024 | |
| Sumitomo Pharma America, INC. | $26.26 | 2023 | Orgovyx |
| Pharming Healthcare, INC. | $24.90 | 2023 | Ruconest |
| Fennec Pharmaceuticals, INC. | $24.10 | 2024 | Pedmark |
| Emd Serono, INC. | $23.56 | 2024 | |
| Blueprint Medicines Corporation | $22.41 | 2024 | Ayvakit |
| Cardinal Health 414 LLC | $22.17 | 2023 | |
| Sobi, INC | $21.13 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2023 | Libtayo |
| Alnylam Pharmaceuticals INC. | $16.71 | 2023 | Givlaari |
| Servier Pharmaceuticals LLC | $16.03 | 2024 | |
| Tempus Ai, INC | $13.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vatsala Katragadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.